|Dr. Jacinth K. Fairley||CEO, MD & Exec. Director||N/A||N/A||1963|
|Mr. Nigel J. Baade B.Com, CPA, Grad. Dip.||CFO & Company Sec.||N/A||N/A||N/A|
|Dr. A. Eglezos BSc(Hons),Ph.D., MBA||VP of Bus. Devel.||N/A||N/A||N/A|
|Dr. Jeremy R. Paull BSc (Hons), Ph.D.||VP of Devel. & Regulatory Affairs||N/A||N/A||N/A|
|Dr. David J. Owen BSc(Hons) Ph.D.||VP of Research||N/A||N/A||N/A|
Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company focuses on the development of VivaGel, which has completed Phase III clinical trials for the management and prevention of bacterial vaginosis, and as a condom coating for the prevention of sexually transmitted infections, as well as VivaGel condom, an antiviral condom. It also develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials for the treatment of a range of tumors, such as breast, prostate, and lung; and DEP cabazitaxel that is in Phase 1/2 clinical trial for solid tumors, as well as DEP irinotecan, an anti-cancer drug used to treat colorectal cancer. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Starpharma Holdings Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.